A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2023-01-23
Target enrollment:
Participant gender:
Summary
This is a first-in-human (FIH), dose-escalation, PK expansion, monotherapy efficacy
expansion, and open-label phase I clinical study assessing the safety, tolerability,
pharmacokinetics, immunogenicity, and preliminary efficacy of QL1604 injection （a humanized
anti-PD-1 monoclonal antibody）in patients with advanced solid tumors.